Trials / Recruiting
RecruitingNCT06400472
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 495 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Conditions
- Ovarian Neoplasms
- Endometrial Neoplasms
- Uterine Cervical Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
- Pancreatic Neoplasm
- Colorectal Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4170156 | Intravenous |
| DRUG | bevacizumab | IV |
| DRUG | carboplatin | IV |
| DRUG | Itraconazole | oral |
| DRUG | pembrolizumab | IV |
Timeline
- Start date
- 2024-05-20
- Primary completion
- 2027-02-01
- Completion
- 2027-04-01
- First posted
- 2024-05-06
- Last updated
- 2026-01-14
Locations
23 sites across 7 countries: United States, Australia, France, Italy, Japan, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06400472. Inclusion in this directory is not an endorsement.